13Jun 2024
Study Finds Topical Tacrolimus Lacks Efficacy in Preventing Rejection in High-Risk Corneal Transplant Patients

Study Finds Topical Tacrolimus Lacks Efficacy in Preventing Rejection in High-Risk Corneal Transplant Patients

A recent study evaluated the efficacy and safety of topical tacrolimus (TAC) in high-risk penetrating keratoplasty (PKP) patients. Participants were randomly assigned to receive either 0.1% TAC ophthalmic suspension or artificial tears for 52 weeks post-surgery, with a regimen of 0.1% betamethasone for 13 weeks followed by 0.1% fluorometholone. Among the 30 enrolled patients, 12 in the TAC group and 13 in the AT group completed the study. No serious adverse effects or rejection episodes were observed in the TAC group, although one rejection episode occurred in the AT group. The study found no significant differences in graft clarity, visual acuity, intraocular pressure, or corneal endothelial cell density between the two groups. Despite demonstrating good tolerability, the study did not establish the efficacy of 0.1% TAC in preventing immunological rejection in high-risk PKP patients.

  • #ophthalmology

Like

Save

Share